Δ^9 -tetrahydrocannabinolic acid A: a reliable marker for differentiating between the consumption of illegal cannabis products and legal, medical Δ^9 -THC

Angeliki Kyriazou¹, Fotios Chatzinikolaou¹, Dimitrios Koutsoukis¹, Antonios Goulas², Georgios Sidiras¹, Nikolaos Raikos^{1*}

¹Laboratory of Forensic Medicine and Toxicology, Medical School, Aristotle University, 54124 Thessaloniki, Greece ²Department of Pharmacology, Medical School, Aristotle University of Thessaloniki

ABSTRACT: Δ^9 -Tetrahydrocannabinolic acid A (Δ^9 -THCA-A) is the biosynthetic precursor of Δ^9 -tetrahydrocannabinol (Δ^9 -THC) in plant material of cannabis sativa, without having psychoactive effects . Δ^9 -THCA-A is not contained in pharmaceutical Δ^9 -THC formulations. Thus, Δ^9 -THCA-A can serve as a marker for differentiating between the consumption of illegal cannabis products and legal fully synthetic Δ^9 -THC.

Key Words: Cannabis, Δ^9 - tetrahydrocannabinol, Δ^9 - tetrahydrocannabinolic acid

Cannabis is the most popular recreational drug globally ¹. The resin of Cannabis plant contains more than 84 chemical compounds with psychoactive effects, known as cannabinoids, the most efficacious of which is Δ^9 -tetrahydrocannabinol (Δ^9 -THC)². The biogenesis of Δ^9 -THC starts with olivetolic acid, that is produced in the plant from the condensation of hexanoyl-CoA with three molecules of malonyl-CoA. In the next step, olivetolic acid is alkylated to cannabigerolic acid, which is then converted to cannabinolic acid. Cannabinolic acid is the precursor of Δ^9 -tetrahydrocannabinolic acid A (Δ^9 -THCA-A or Δ^9 -THCA). Δ^9 -THCA-A is a non-psychoactive substance that is decarboxylated to Δ^9 -THC via heating, when cannabis products are smoked ³.

The therapeutic effects of Δ^9 -THC have been known since ancient times, when cannabis was used as a medicine for many different pathological conditions such as insomnia, headaches, gastrointestinal disorders and pain⁴. Nowadays the cultivation,

possession and transfer of cannabis is illegal in most of the European countries and is convicted by law. On the other hand, medical Δ^9 -THC is provided, mainly in the U.S, to treat a range of diseases and the ensuing symptoms. Marinol[®] (U.S, Canada) is an oral drug containing fully synthetic Δ^9 -THC, known as dronabinol and is used to treat anorexia in people suffering from AIDS, and also to minimize nausea and vomiting associated with cancer therapy⁵. Another popular pharmaceutical compound, used to treat spasticity and neuropathic pain associated with multiple schlerosis, is Sativex[®] (U.S, Europe, New Zealand). Sativex[®] is an oronucosal spray which contains nabiximols, a mixture of compounds derived from cannabis plant. The principal cannabinoid components of the drug are synthetic Δ^9 -THC and cannabidiol⁶.

The high popularity of illegal cannabis and the use of legal fully synthetic Δ^9 -THC in recent years, demonstrated the need to find reliable markers in biological samples for differentiating between the consumption of illegal cannabis products and legal medication containing fully synthetic Δ^9 -THC.

 Δ^9 -THCA-A could serve as a marker of illegal consumption of cannabis products if the substance is detected in biological samples of cannabis users. Δ^9 -THCA-A attracted scientists' attention in recent years, as it is the precursor substance of natural Δ^9 -THC in plant material and is not contained in Marinol[®] or Sativex[®]. In 2005, it was shown that during smoking cannabis joint, Δ^9 -THCA-A is only partially converted to Δ^9 -THC and therefore it can be taken up by the consumer ⁷.

In 2007, Jung et al. detected Δ^9 -THCA-A in the urine and blood serum samples collected from police controls of drivers suspected for driving under the influence of drugs chromatography (DUID). Liquid tandem-mass spectrometry (LC-MS/MS) was used for Δ^9 -THCA-A determination. Δ^9 -THCA-A was detected in the urine and blood serum samples of cannabis users in concentrations of up to 10.8 ng/ml in urine and 14.8 ng/ml in serum. The concentration of Δ^9 -THC was higher than the concentration of Δ^9 -THCA-A in most serum samples ⁸. In the above paper, Δ^9 -THCCOOH-D3 was used as internal standard (IS) because the isotopically labeled Δ^9 -THCA-A was not commercially available.

In 2012, Roth et al. succeeded to synthesize deuterated Δ^9 -THCA-A⁹. Metabolism studies of Δ^9 -THCA-A in rats showed that the main metabolites of THCA-A were formed in close analogy to Δ^9 -THC metabolism and twelve metabolites were identified¹⁰.

In 2013, Brabanter N. et al. developed a fast method for quantification of Δ^9 -THCA-A in urine using microwaveaccelerated derivatization and gas chromatography–triple quadrupole mass spectrometry. Their method could quantify Δ^9 -THCA-A in 30 min, using only 1 mL of urine

In 2013, Raikos N. et al. analyzed fifty eight authentic whole blood and the respective plasma samples collected from drivers suspected for driving under the influence of cannabis, using LC-MS/MS. Δ^9 -THCA-A concentrations ranged from 1.0 to 496 ng/mL in blood samples and from 1.4 to 824 ng/mL in plasma samples. Δ^9 -THC was present in all blood samples with levels ranging from 0.7 to 51 ng/mL. The plasma:blood partition coefficient had a mean value of 1.7¹².

In 2010, Auwarter et al. concluded that Δ^9 -THCA-A can be incorporated in hair only by external contamination e.g. by condensate of smoked cannabis material and not by blood

^{*}Corresponding author: Raikos Nikolaos, Laboratory of Forensic Medicine and Toxicology, Medical School, Aristotle University, 54124 Thessaloniki, Tel.:+30 2310 999206, Fax: +30 2310 999216, email: raikos@med.auth.gr

or sweat and Δ^9 -THCA-A could be a valuable marker for external cannabinoid contamination of hair ¹³.

In conclusion, Δ^9 -THCA-A can be detected in blood and urine samples of cannabis consumers and this detection in biological fluids may serve as a marker for differentiating

between the intake of legally prescribed Δ^9 -THC medication and illegal cannabis products. However, the knowledge about its usefulness in forensic cases is very limited and further research is needed.

Δ⁹-τετραϋδροκανναβινολικό οξύ Α: ένας αξιόπιστος δείκτης για τη διάκριση μεταξύ της χρήσης παράνομων προϊόντων της κάνναβης και της λήψης φαρμακευτικής Δ⁹-THC.

Κυριάζου Αγγελική¹, Χατζηνικολάου Φώτιος¹, Κουτσούκης Δημήτριος¹, Γούλας Αντώνιος², Σιδηράς Γεώργιος¹, Ράικος Νικόλαος^{1*}

¹Εργαστήριο Ιατροδικαστικής και Τοζικολογίας, Ιατρική Σχολή, Α.Π.Θ., 54124 Θεσσαλονίκη ²Εργαστήριο Φαρμακολογίας, Ιατρική Σχολή, Α.Π.Θ., 54124 Θεσσαλονίκη

ΠΕΡΙΛΗΨΗ: Το Δ⁹-τετραϋδροκανναβινολικό οξύ A (Δ⁹-THCA-A) αποτελεί την πρόδρομη ουσία της Δ⁹τετραϋδροκανναβινόλης (Δ⁹-THC) στο φυτό cannabis sativa, χωρίς ψυχοδραστικές ιδιότητες. Το Δ⁹-THCA-A δεν εμπεριέχεται στα φαρμακευτικά προϊόντα που περιέχουν συνθετική Δ⁹-THC. Συνεπώς το Δ⁹-THCA-A μπορεί να χρησιμεύσει ως ένας δείκτης για τη διάκριση μεταξύ της χρήσης παράνομων προϊόντων της κάνναβης και της λήψης φαρμακευτικής Δ⁹-THC.

Λέξεις Κλειδιά: Κάννα $\beta\eta$, Δ^9 -τετραϋδροκαννα β ινόλη, Δ^9 -τετραϋδροκαννα β ινολικό οζύ Α

REFERENCES

- 1. EMCDDA: "A cannabis reader. Global issues and local experiences: Perspectives on cannabis controversies, treatment and regulation in Europe." European Monitoring Centre for Drugs and Drug Addiction (2007), Lisbon.
- 2. Ethan B. Russo: "Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential." *Routledje* (2013), 28.
- Steve J. Gagne, Jake M. Stout, Enwu Liu et al.: "Identification of olivetolic acid cyclase from Cannabis sativa reveals a unique catalytic route to plant polyketides." *PNAS* (2012), 109 (31):12811-16.
- Procon.org "History of Marijuana as Medicine 2900 BC to Present" http://medicalmarijuana.procon.org/view.timeline.php?
- timelineID=000026.5. Product Information of Marinol1, Unimed Pharmaceuticals, Mariette, GA, USA (2006).
- Wade D, Makela P, House H, Bateman C, Robson P: "Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosi." *Mult Scler* (2006) 12 (5): 639–45.
- Dussy F.E, Hamberg C, Luginbuhl M, Schwerzmann T, Briellmann T.A: "Isolation of D9-THCA-A from hemp and analytical aspects concerning the determination of D9-THC in cannabis products," *Forensic Sci. Int.* (2005), 149:3–10.
- Jung J, Kempf J, Mahler H, Weinmann W: "Detection of 19-tetrahydrocannabinolic acid A in human urine and blood serum by LC–MS/MS." *J. Mass Spectrom*. (2007), 42:354–360.

- Roth N, Wohlfarth A, Muller M, Auwarter V: "Regioselective synthesis of isotopically labeled D9- tetrahydrocannabinolic acid A (THCA-A-D3) by reaction of D9-tetrahydrocannabinol-D3 with magnesium methyl carbonate." *Forensic Science International* (2012), 222:368–372.
- Jung J, Meyer M.R, Maurer H.H, Neususs C, Weinmann W, Auwarter V: "Studies on the metabolism of the D9-tetrahydrocannabinol precursor D9-tetrahydrocannabinolic acid A (D9-THCA-A) in rat using LC–MS/MS, LC–QTOF MS and GC–MS techniques" J. Mass Spectrom (2007) 44:1423–1433.
- 11. Brabanter N, Gansbeke W. et al.: "Fast quantification of 11-nor-D9-tetrahydrocannabinol-9-carboxylic acid (THCA) using microwave-accelerated derivatisation and gas chromatography-triple quadrupole mass spectrometry." *Forensic Science International* (2013) 90-95.
- Raikos N, Schmid H, Roth N, Auwärter V, Lanz S, Läng A, König S, Weinmann W: "Determination of delta-9 tetrahydrocannabinolic acid A (delta-9-THCA-A) in whole blood and plasma by LC-MS/MS and application in authentic samples from drivers suspected of driving under the influence of cannabis." *51st Annual Meeting of The International Association of Forensic Toxicologists,* Poster Session (2013).
- 13. Auwarter V, Wohlfarth A, Traber J, Thieme D, Weinmann W: "Hair analysis for $\Delta 9$ -tetrahydrocannabinolic acid A—New insights into the mechanism of drug incorporation of cannabinoids into hair" *Forensic Sci. Int.* (2010) 196 :10–13.